Kite Pharma appoints Chris Nowers as Head of Europe

pharmafile | October 14, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chris Nowers, London, kite pharma 

Kite Pharma announced on 13 October that it had appointed Chris Nowers as its Head of Europe. Nowers will be based in London and his new role will see him oversee European commercial operations to build awareness of Kite’s pipeline portfolio of Car and t-cell receptor therapies. He will also prepare for the potential launch of the company’s lead product candidate, KTE-C19.

Mr Nowers arrives with 30 years of commercial leadership experience in the pharmaceutical, biotech and diagnostics sectors. Prior to joining Kite, Nowers held senior commercial leadership positions at Bristol-Myers Squibb, including Head of Immuno-oncology and Hematology in France, where he led the launch of Opdivo (nivolumab), and as Vice President of Global Commercialization for Yervoy (ipilimumab), where he led the global commercial launch. Previously, Nowers was Vice President of Sales and Marketing at Genomic Health, and Chief Executive Officer of Avantogen Oncology, a company developing early-stage cancer therapeutics. Nowers also served 11 years at Amgen in a variety of commercial leadership roles, including Global Commercial Leader for Neurology and European Director for Oncology and Hematology.

Commenting upon his appointment, Arie Belldegrun, M.D., Chairman, President and Chief Executive Officer of kite, stated: “The addition of Chris Nowers to our executive team will be instrumental to Kite as we expand our global footprint…The breadth of Chris’ commercial experience in global immuno-oncology is impressive, and makes him well-qualified to propel our pipeline of CAR-T and TCR therapy candidates to treat both blood-based and solid cancers into international markets.”

Looking ahead to working with Kite, Nowers said “Kite is a truly innovative company at the cusp of transforming the paradigm of cancer treatment, and I am honored to play a role in bringing what could potentially be life-changing therapies to patients around the world. I look forward to working with such a dynamic and passionate team to advance our presence in Europe and continue our efforts in developing novel approaches in engineered cell therapy.” (This can be cut, if needed).

Related Content

Touchlight completes expansion of one of world’s largest DNA manufacturing facilities in London

Touchlight, a company that focuses on pioneering enzymatic DNA production, has announced that it has …


EMA’s CHMP recommends conditional approval for Kite Pharma’s CAR T therapy for mantle cell lymphoma

Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy known as KTE-X19 has received …


MSD unveils plans for $1.3bn central London research centre

MSD has lifted the lid on plans to build a $1.3 billion research centre in …

Latest content